Author(s)
Di Rienzo P1, Zarrelli L2, Mennini FS3, Marcellusi A3, Bini C4, Malcolm B5, May J6, Gooden KM7, Van de Wetering G8, Smith van Carroll LE9
1Bristol-Myers Squibb, Roma, Italy, 2Bristol Myers Squibb, Rome, Italy, 3Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome Tor Vergata, Rome, Italy, 4Faculty of Economics, Centre for Economic and International Studies (CEIS)-Economic Evaluation and HTA (EEHTA), University of Rome Tor Vergata, Roma, Italy, 5Bristol-Myers Squibb, Middlesex, UK, 6Bristol-Myers Squibb, Uxbridge, UK, 7Bristol-Myers Squibb, Lawrenceville, NJ, USA, 8Pharmerit International, Rotterdam, Netherlands, 9Pharmerit International, York, NYK, UK
OBJECTIVES: Nivolumab in combination with ipilimumab (nivolumab+ipilimumab) is the first immuno-oncology combination that has shown significant, long-term overall survival (OS) benefit for the first-line treatment of adult patients with intermediate- or poor-risk advanced renal cell carcinoma (1L RCC) compared with standard of care (sunitinib). This study assessed the cost-effectiveness of nivolumab+ipilimumab compared with sunitinib in 1L RCC from a healthcare system perspective in Italy. METHODS: A three-state partitioned survival model (progression-free disease, progressed disease, death) was developed with a 40-year time horizon and a one-week cycle length. Survival, adverse event, and treatment-specific utility (EQ-5D-3L) data were sourced from the CheckMate-214 trial (NCT02231749); survival was extrapolated over the model time horizon. Costs for adverse events, drug acquisition, drug administration, monitoring and subsequent therapies were obtained from the published literature, DRG tariffs and AIFA; while associated resource use was based on CheckMate-214 and obtained through clinical expert input. An annual discount of 3.0% was applied to both costs and effects. Outcomes of interest were total costs, life years (LYs), quality-adjusted life-years (QALYs), incremental cost-effectiveness ratio (ICER) and incremental cost-utility ratio (ICUR). Furthermore, as a confidential discount already applies in Italy for both nivolumab and ipilimumab, two scenarios investigated the required price reduction on nivolumab+ipilimumab to reach an ICUR of €30,000/QALY and €20,000/QALY. RESULTS: Nivolumab+ipilimumab was associated with higher total LYs and QALYs (5.66 LYs and 4.89 QALYs) versus sunitinib (4.32 LYs and 3.63 QALYs) at increased total cost (€115,095 versus €61,226, respectively). This resulted in an ICER of €40,143/LY and an ICUR of €42,521/QALY versus sunitinib. Price reduction of 9.91% and 30.06% for nivolumab+ipilimumab would be required to reach ICURs of €30,000/QALY and €20,000/QALY, respectively. CONCLUSIONS: Driven by the increased and sustained OS benefit seen in CheckMate-214, nivolumab+ipilimumab is cost-effective versus sunitinib for the treatment of previously untreated 1L RCC in Italy.
Conference/Value in Health Info
2019-11, ISPOR Europe 2019, Copenhagen, Denmark
Code
PCN170
Topic
Economic Evaluation
Topic Subcategory
Trial-Based Economic Evaluation
Disease
Drugs, Oncology
